Goldman Sachs Group Inc Clene Inc. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.33 - $73.0 $4,356 - $963,673	-13,201 Reduced 50.49%	12,944 $36,000
Q3 2022 Nov 10, 2022	SELL	$0.33 - $73.0 $4,356 - $963,673	-13,201 Reduced 50.49%	12,944 $0
Q2 2022 May 14, 2024	BUY	$2.1 - $4.12 $54,904 - $107,717	26,145 New	26,145 $66,000
Q2 2022 Aug 15, 2022	BUY	$2.1 - $4.12 $17,350 - $34,039	8,262 Added 46.2%	26,145 $66,000
Q1 2022 May 16, 2022	BUY	$2.42 - $4.42 $43,276 - $79,042	17,883 New	17,883 $70,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $279M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.